ASC Economics: Why Total Joints Are Moving to Surgery Centers

The financial logic behind moving total joints to ambulatory surgery centers is compelling — and more precarious than it first looks. ASC total joint reimbursement sits well below the inpatient and hospital-outpatient equivalents, which is exactly why payers and health systems have pushed these cases outpatient. But that same downward pressure is now squeezing the centers doing the work. This post lays out the cost gap, the system-level savings, and why the falling-reimbursement caveat turns operating efficiency into the real survival lever.

For the clinical and policy background on this shift, start with the pillar guide to outpatient total joint arthroplasty; this post is the money half of that story.

The cost gap between inpatient, HOPD, and ASC

The migration runs across three settings, in descending cost order: traditional hospital inpatient, hospital outpatient department (HOPD), and freestanding ASC. The ASC's structural advantage is lower overhead, leaner staffing models, and shorter stays — an academic-center analysis of a short-stay pathway for outpatient total joints found shorter length of stay and modestly lower encounter costs versus an inpatient discharge, in a selected population.

Multiply a per-case advantage across a fast-growing case volume and the system-level number gets large.

How much the system saves per case

A Medicare Part A and B utilization and reimbursement analysis quantified it. Between 2019 and 2022, ASC total joint volume surged 327 percent, and by 2022 ASCs accounted for about 8.6 percent of all total joint arthroplasties. The shift corresponded to roughly $235 million per year in savings versus inpatient settings and about $137 million versus HOPD.

That is the number that gets total joints onto the ASC roadmap of every health system and payer. But it is a system savings figure — and the entity capturing the case is not the entity capturing all of that saving.

The reimbursement-pressure caveat

Here is the part that does not make the press release: the same analysis found that ASC reimbursement per total joint has been declining in real terms — about 8.1 percent after adjusting for inflation across the study period, even as volume climbed. The structural cost advantage that makes the ASC attractive is simultaneously being competed and regulated down from the top line.

Why efficiency is the survival lever as reimbursement falls

When you cannot raise the price, margin has only one place left to come from: doing more, safely, within the same fixed block of staffed time. That moves the margin conversation out of the contract and into the schedule.

Concretely, in a fixed-fee outpatient total-joint program, the levers are the OR efficiency metrics that actually matter — strong first case on-time starts, fast and safe turnovers, and disciplined block utilization. A recovered minute is not abstract here; it converts almost directly into protected margin or one more case in the day. Safety is the non-negotiable constraint on all of it, which is why patient selection and outcomes sit alongside the economics rather than behind them.

How ORbit protects ASC margins through utilization

If margin now lives in the schedule, you need to see the schedule the way you see the P&L. ORbit gives an outpatient joints program a median-based, facility-scoped view of on-time starts, turnover-time distributions, and block utilization — broken out by surgeon and service line — so the minutes that quietly become margin (or quietly leak away) are visible and managed, not estimated at quarter-end. When reimbursement is falling, the centers that win are the ones that run tightest. The fastest way to find your own leak points is to see them on your own data.